share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Newman James W. Jr.

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股变动声明
美股SEC公告 ·  03/27 18:25

Moomoo AI 已提取核心信息

James W. Newman Jr., a reporting person for Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock. The action took place on March 25, 2024. However, the announcement did not disclose the nature of the transaction, including the action type, status, number of shares involved, transaction price, or the resulting number of shares held after the action. Without these details, the total value of the shares cannot be determined. The relationship of Newman to the issuer was also not specified in the provided information.
James W. Newman Jr., a reporting person for Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock. The action took place on March 25, 2024. However, the announcement did not disclose the nature of the transaction, including the action type, status, number of shares involved, transaction price, or the resulting number of shares held after the action. Without these details, the total value of the shares cannot be determined. The relationship of Newman to the issuer was also not specified in the provided information.
阿迪尔制药公司（ADIL）的举报人小詹姆斯·纽曼参与了一项涉及该公司股票的交易。该行动于 2024 年 3 月 25 日进行。但是，该公告没有透露交易的性质，包括行动类型、状态、所涉股票数量、交易价格或行动后由此产生的持股数量。没有这些细节，就无法确定股票的总价值。所提供的信息中也没有具体说明纽曼与发行人的关系。
阿迪尔制药公司（ADIL）的举报人小詹姆斯·纽曼参与了一项涉及该公司股票的交易。该行动于 2024 年 3 月 25 日进行。但是，该公告没有透露交易的性质，包括行动类型、状态、所涉股票数量、交易价格或行动后由此产生的持股数量。没有这些细节，就无法确定股票的总价值。所提供的信息中也没有具体说明纽曼与发行人的关系。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间